The safety of beclomethasone dipropionate in the treatment of ulcerative colitis.

The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. Expert Opin Drug Saf. 2018 Aug 11;: Authors: Rizzello F, Mazza M, Salice M, Calabrese C, Calafiore A, Campieri M, Gionchetti P Abstract INTRODUCTION: Beclomethasone dipropionate (BDP) is a second-generation corticosteroid that use novel drug technologies to ensure colonic targeting and potentially reducing systemic corticosteroid concentrations. It is approved for treatment of patients with mild-to-moderate ulcerative colitis (UC) who do not respond to mesalazine. The gut-selective mechanism of action has the potential to improve the safety profile of beclomethasone dipropionate compared to other conventional corticosteroids. Areas covered: We reviewed the mechanism of action, efficacy and safety of beclomethasone dipropionate in the treatment of UC. The positioning of beclomethasone dipropionate in management algorithms is also discussed. Expert opinion: The highly selective mechanism of action of BDP restricts the steroid-related side-effects. BDP is efficacious in the treatment of active UC. Topical formulation is the first-choice in distal UC, while oral formulation is used in patients with an extensive involvement of the colon. The rates of adverse events (AE), serious AEs, and steroid-related side-effects are similar to placebo and mesalamine and slightly inferior to traditional corticosteroids. PMID: 30101623 [PubMed - as supplied by publ...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research